Rob Dillard

DocwireNews

A study assessed autologous CD7 CAR-T therapy in refractory or relapsed r/r T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), which may avoid graft-versus-host disease (GVHD). The results were presented at the 2022 American Society of Clinical Oncology Annual Meeting.This phase I study, conducted by Liping Zhao and colleagues, was comprised of five patients with CD7+&nbsp;r/r T-ALL/LBL and no leukemia cells in peripheral blood, and followed a &ldquo;3+3&rdquo; dose escalation process. The endpoints of interest were adverse events and efficacy.According to the results, all participants in the study experienced grade 3-4 hematological toxicity; however, these recurred to grade 2 within 30 days. One-month post-transfusion, the investigators observed that all but one patient achieved complete remission. The researchers noted that of the four patients who received target dose, the median peak CAR T cell count in peripheral blood was 4.27&times;102/uL (range, 2.49-5.61) by flow cytometry, with the entire study population showing detectable CAR transgene by PCR.&ldquo;Autologous CD7 CAR T cell therapy was safe and effective in the induction of remission in r/r T-ALL/LBL patients, without signs of GVHD,&rdquo; the researchers concluded. They added that &ldquo;longer follow-up time of more cases will be used to further evaluate this therapy.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Assessing Autologous CD7-targeted CAR T-cell Therapy for Acute Lymphoblastic Leukemia/Lymphoma

ASCO 2022

A study assessed autologous CD7 CAR-T therapy in refractory or relapsed r/r T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), which may avoid graft-versus-host disease ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe